Characteristics     Last updated on 2012/2556     11     28, a full moon day;

Active ingredient content in mcg vs. Normative mean % [40~120];

Adequate disorders vs. Hormone level % in pg/mL;

Age in years [15~20, 21~30, 31~40, 41~50, 51~60, 61~70, 71~80, 81~90, 91~100, ... ] vs. % of patient;

Blood mercury level in µg/L [-6 ~ 12] vs. Neurobehavioral physical movement functionality;

BMI in integer vs. Risk factor in integer;

Diabetes: Blood pressure level in mm Hg vs. [HbAc1c level in % ; LDL Cholesterol Level in mg/mL] 3D;

Endometrial cells vs. Endometriotic cells: Endometriosis; [SNP, Sodium Nitroprusside vs. cpm incorporation of Thymidine; 2D] , [Incubation time in hour vs. Nitride product in µM; 2D] , [Peritoneal fluid in % vs. Nitride product in µM; 2D]

IPS Cell, invented by Nippon, in early 21st century (approx. 2002) WHERE the IPS cell can transform into any one BF2 tissues ... ; IPS cell works within 2,3 dimensional environment only (i.e. ACT1 stage and ACT2 stage); IFF 3,4 dimensional, also see: Monbusho level knowledge enhancement for ACT3 stage idea ... ;

Mass Spectrometry in time line vs. (Proteins (VLDL < LDL < HDL) (...));

Serum Calcium in mg/dL [8~11] vs. Parathyroid Hormone in % [0~100];

Stress mPa vertically and horizontally vs. Strain; Ash density = 0.20 g/cm3 [Female age < 20 year]; Ash density = 0.15 g/cm3 [Female age 20 ~ 50 year]; Ash density = 0.10 g/cm3 [Female age 50 ~ 80 year]; Skeletal;

Syndrome with BMI vs. Plasma level active ingredient in µg/ml;

Therapy in quarter-year vs. drug ingredient generic name in mg/dL;

Year vs. Cumulative proportion surviving;

...

Up